Changes to the Purple Book: Progress in Transparency
Getting Lost in the Thicket: AbbVie Wields Its Expansive Humira® Patent Portfolio Against Alvotech’s Adalimumab Biosimilar
The mRNA Patent and Competitive Landscape: Translate BIO; Arcturus; eTheRNA and Other Startups; and LNP Technology (Part II)
The mRNA Patent and Competitive Landscape Through One Year of the COVID-19 Pandemic–Part I
Patent Thickets and Regulatory Challenges Cited as Major Factors Limiting Price Reductions in the Biologic Drug Space
The Federal Circuit Affirms District Court Finding that Sandoz Does Not Infringe Amgen’s Protein Purification Patent
Pfizer Loses Out On Its Follow-On Petition Challenges to Genentech’s anti-HER2 Patents Because It Did Not Follow General Plastics Guidance
How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline
